Acquired Company
Acasti Pharma completed its merger with Grace Therapeutics, Inc. on August 27, 2021.
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a topical bioadhesive film-forming polymer for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey. Show more
103 Carnegie Center, Princeton, NJ, 08540, United States
Start AI Chat
Market Cap
61.0M
52 Wk Range
$1.75 - $4.10
Previous Close
$4.02
Open
$4.07
Volume
97,204
Day Range
$4.05 - $4.30
Enterprise Value
30.54M
Cash
18.67M
Avg Qtr Burn
-2.23M
Insider Ownership
27.06%
Institutional Own.
28.00%
Qtr Updated
12/31/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
GTx-104 Details Aneurysmal subarachnoid hemorrhage (aSAH) | PDUFA Approval decision | |
GTx-101 (Local Anesthetic) Details Postherpetic Neuralgia | Phase 1 Update | |
GTx-102 Details Ataxia-Telangiectasia | Phase 1 Update |
